Expression and Signifi cance of PIRH2 and P53 Proteins in Esophageal Squamous Cell Carcinoma Tissues
-
摘要: 目的 研究泛素连接酶2（PIRH2）和P53蛋白在食管鳞癌组织中的表达及意义。方法 采用SP法检测44例食管鳞癌组织、不典型增生组织和正常食管黏膜组织中PIRH2和P53蛋白的表达。结果 (1) PIRH2在食管鳞癌组织、不典型增生组织和正常食管黏膜组织中表达率分别为88.64%、68.18%和25%，组间两两比较，差异均具有统计学意义（P均<0.016）；P53蛋白在食管鳞癌组织、不典型增生组织以及正常食管黏膜组织中表达率分别为43.18%、38.64%和0，正常组织分别与癌组织及不典型增生组比较，差异均具有统计学意义（P均<0.016）。(2)PIRH2在食管鳞癌组织中的表达与肿瘤的分化程度、浸润深度、淋巴结转移及患者年龄、性别等临床病理特征均无相关性(P均>0.05)；P53 蛋白的表达与肿瘤患者的年龄、性别、癌组织的浸润深度、淋巴结转移均无相关性（P均>0.05），但与肿瘤的分化程度呈显著性相关（P<0.05）。(3)PIRH2和P53蛋白在食管鳞癌组织中的表达无明显相关性(P>0.05)。结论 PIRH2与P53蛋白的高表达均与食管鳞癌发生发展相关，可作为食管癌新的诊断指标。PIRH2可能主要通过促进P53蛋白（野生型）的降解从而降低P53蛋白（野生型）的抑癌活性，促进食管鳞癌的发生，而对P53蛋白(突变型)并无明显作用。Abstract: Objective To study the expression and signifi cance of PIRH2 and P53 in esophageal squamous cell carcinoma tissues. Methods SP method was used to examine the expression of PIRH2 and P53 in 44 tissues of esophageal squamous cell carcinom, atypical hyperplasia and normal esophageal mucosa. Results (1) Positive expression rates of PIRH2 were 88.64%, 68.18% and 25% in tissues of squamous carcinoma, atypical hyperplasia and normal esophageal mucosa, respectively. There were signifi cant differences between any two groups (P<0.016). Expressions of P53 protein were 43.18%, 38.64% and 0 in tissues of squamous carcinoma, atypical hyperplasia, and normal esophageal mucosa, respectively. There were significant differences between normal esophageal mucosa and other groups (P<0.016).(2) The expression of PIRH2 had no relationship with the differentiation grade of carcinoma,invasion,lymph node metastasis,patient′s age and gender (P>0.05). The expression of P53 protein had no relationship with the differentiation invasion, lymph node metastasis,patient's age and gender (P>0.05), but with signifi cant correlation with the differentiation grade of carcinoma (P<0.05).(3) The expression of PIRH2 had no correlation with P53 in esophageal squamous cell carcinoma tissues. Conclusion The high expression of PIRH2 and P53 protein may play an important role in the development and evolution of esophageal squamous cell carcinoma,to be the new data to make judgment of esophageal carcinoma. PIRH2 could degrade wtP53 and inhibit the activity of wtP53, to promote the occurrence of esophageal squamous cell carcinoma,but without obvious effect on mtP53.
-
Key words:
- PIRH2 /
- P53 /
- Esophageal squamous carcinoma /
- Immunohistochemical
-
-
[1] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 20 02[J]. CA Cancer J Clin,2005,55(2):74-108. [2] Bennett WP, Hollstein MC, Metcalf RA, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis[J]. Cancer Res,1992,52(21):6092-7. [3] Wang LD, Zhou Q, Hong JY, et al. p53 protein accumulation and gene mutations in multifocal esophageal precancerous lesions from symptom free subjects in a high incidence area for esophageal carcinoma in Henan, China[J]. Cancer,1996,77(7):124 4-9. [4] Yuan JM,Ling ZQ,Mao WM.The research progress of p53 in esophageal cancer[J]. Guo Ji Xiao Hua Bing Za Zhi, 20 12,32(2):90-2. [袁嘉敏，凌志强，毛伟敏. p53在食管癌中的 研究进展[J]. 国际消化病杂志,2012,32(2):90-2.] [5] Chen ZY.Relationship between p53 expression and proliferation and apoptosis in esophageal carci-noma development[J].Zhong Liu Fang Zhi Yan Jiu, 2011，38(8): 918-20. [陈正言.食管黏膜癌 变过程中组织细胞增殖、凋亡和p53表达的变化[J]. 肿瘤防治 研究，2011,38(8): 918-20.] [6] Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation[J]. Cell,2003,112(6):779-91. [7] Qiu YY,Dong LL,Zhu GG,et al. Research progress in association between the ubiquitin ligase Pirh2 and tumors[J].Zhong Liu, 2011,31(4):369-73. [邱艳艳，董兰兰，朱果果， 等. 泛素连接酶Pirh2与恶性肿瘤相关性的研究进展[J].肿 瘤,2011,31(4):369-73.] [8] Chava S, Mohan V, Shetty PJ, et al. Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer[J]. Dis Esophagus,2012,25(1):81-7. [9] Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops[J]. Oncogene,2005,24(17):2899-908. [10] Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas[J]. Cancer Res,1993,53(4):846-50. [11] Shloush J, Vlassov JE, Engson I, et al. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2[J]. J Biol Chem,2011,286(6):4796-808. [12] Tai E, Benchimol S. TRIMming p53 for ubiquitination[J]. Proc Natl Acad Sci U S A,2009,106(28):11431-2. [13] Hakem A, Bohgaki M, Lemmers B, et al. Role of Pirh2 in mediating the regulation of p53 and c-Myc[J]. PLoS Genet,2011,7(11):e1002360. [14] Jung YS??Qian Y??Chen X.Pirh2 RING-finger E3 ubiquitin ligase:its role in tumorigenesis and cancer therapy[J].FEBS Lett?? 20 12??586(10):1397-402. [15] Wang Z, Yang B, Dong L, et al. A novel oncoprotein Pirh2: rising from the shadow of MDM2[J]. Cancer Sci,2011,102(5):909-17.
计量
- 文章访问数: 1197
- HTML全文浏览量: 23
- PDF下载量: 590
下载:
